Even the strong franc can’t have a negative influence on Novartis’ investments into Basel, Jörg Reinhardt said in an interview published in the "Aargauer Zeitung". “We’re running a business for the long term, just like our investments,” said the company’s president. There are no plans to slow the major investments in the Basel campus.
Overseas growth won’t change the role of Basel as the company’s global headquarters either. “Just as before, an important part of our research and development is in Basel and this won’t change.” Collaboration with the University of Basel will be intensified in the future.
Also important for the company is its employees; Swiss professionals are highly trained, according to Reinhardt, and Novartis itself trains around 300 apprentices in Basel each year. The company also needs workers from abroad, though Reinhardt emphasises that they won’t take jobs away from the Swiss.